Safety and efficacy of elexacaftor/tezacaftor/ivacaftor in adolescents and adults with cystic fibrosis and F508del-gating and F508del-residual function genotypes: Results from an open-label extension study

RATIONALE: In an 8-week, active-controlled, phase 3 study (445-104), elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) was shown to be efficacious and safe in participants 

• Chmiel, J. F.
• McBennett, K.
• Quon, B. S.
• Colombo, C.
• De Wachter, E.
• Fajac, I.
• Mondejar-Lopez, P.
• Polineni, D.
• Robinson, P.
• Sutharsan, S.
• Mall, M. A.
• McKone, E. F.
• Ramsey, B.
• Taylor-Cousar, J. L.
• Tullis, E.
• Suresh, N. E.
• Zhang, Y.
• Sosnay, P.
• Jennings, M.
• Barry, P. J.